Overview

Trivalent Salmonella Conjugate Vaccine (TSCV)

Status:
Not yet recruiting

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.

Phase:

Phase 2

Details

Lead Sponsor:

University of Maryland, Baltimore

Collaborators:

Bharat Biotech International
Wellcome Trust